Becton Dickinson and Company (BDX) : $42.39 million worth of transactions were on upticks in Becton Dickinson and Company (BDX), compared to $29.49 million on downticks. The ratio between the two was 1.44, whereas, the net money flow stood at a healthy $12.9 million on Mondays session. The consistent buying on upticks in the stock accounted for $12.05million worth of trades. The total money flow into the stock stood at $12.05 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.39%. The stock was trading at $174.4, with a drop of $0.68 over the previous days close. The stock recorded -0.71% for the week.
Becton, Dickinson and Company is up 9.78% in the last 3-month period. Year-to-Date the stock performance stands at 14.13%. Becton, Dickinson and Company has dropped 1.11% in the last five trading days, however, the shares have posted positive gains of 4.24% in the last 4 weeks. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (VP, Corp Finance and Treasurer) of Becton Dickinson & Co, Gallagher John E had sold 1,931 shares worth of $328,019 in a transaction dated June 13, 2016. In this transaction, 1,931 shares were sold at $169.87 per share.
Becton Dickinson and Company (NYSE:BDX): On Mondays trading session , Opening price of the stock was $175.5 with an intraday high of $176.01. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $173.51. However, the stock managed to close at $174.4, a loss of 0.39% for the day. On the previous day, the stock had closed at $175.08. The total traded volume of the day was 876,567 shares.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.